Heparin is a medication used in this trial to help increase the yield of stem cell collection from patients with lymphoma or myeloma. It is given as a single dose before the collection process. The purpose of using heparin in this trial is to see if it can effectively improve the number of stem cells collected from the blood, which can be important for future treatments.

Multiple Myeloma – Multiple Myeloma is a type of cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. As the disease progresses, abnormal plasma cells multiply and accumulate in the bone marrow, leading to bone damage and affecting the production of normal blood cells. This can result in symptoms such as bone pain, fatigue, and frequent infections. Over time, the disease can cause complications like anemia, kidney problems, and weakened bones. The progression of Multiple Myeloma can vary, with periods of stability and periods of active disease.

Lymphoma – Lymphoma is a group of blood cancers that develop in the lymphatic system, which is part of the body’s immune system. It begins when a type of white blood cell, called a lymphocyte, grows uncontrollably. As the disease progresses, these abnormal cells can form tumors in lymph nodes and other parts of the body. Symptoms may include swollen lymph nodes, fever, night sweats, and weight loss. Lymphoma can be classified into two main types: Hodgkin lymphoma and non-Hodgkin lymphoma, each with different patterns of progression. The disease can spread to other organs and tissues, affecting their function.